Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Treasury Shares (2021 - 2025)

Cytek Biosciences' Treasury Shares history spans 5 years, with the latest figure at $5.1 million for Q2 2025.

  • For Q2 2025, Treasury Shares rose 1057.97% year-over-year to $5.1 million; the TTM value through Jun 2025 reached $5.1 million, up 1057.97%, while the annual FY2023 figure was $5.3 million, 355.98% up from the prior year.
  • Treasury Shares reached $5.1 million in Q2 2025 per CTKB's latest filing, down from $9.3 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $9.3 million in Q3 2024 to a low of $104876.0 in Q4 2021.
  • Average Treasury Shares over 5 years is $2.7 million, with a median of $1.2 million recorded in 2022.
  • Peak YoY movement for Treasury Shares: tumbled 89.88% in 2023, then soared 1057.97% in 2025.
  • A 5-year view of Treasury Shares shows it stood at $104876.0 in 2021, then skyrocketed by 1015.13% to $1.2 million in 2022, then soared by 355.98% to $5.3 million in 2023, then soared by 73.5% to $9.3 million in 2024, then plummeted by 44.39% to $5.1 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Treasury Shares are $5.1 million (Q2 2025), $9.3 million (Q3 2024), and $444319.0 (Q2 2024).